Follow-up should aim to maintain normoprolactinemia, monitor the residual tumor via imaging (ideally with MRI at six months after initiating treatment, then annually if stable), and assess serum PRL levels every three to six months during the first year, then biannually thereafter. This evidence concerns the gene PRL and neoplasm.